Resolving the daratumumab interference with blood compatibility testing. - Wikidata - wikimedia - TriplyDB

Resolving the daratumumab interference with blood compatibility testing.

Resolving the daratumumab interference with blood compatibility testing.

http://www.wikidata.org/entity/Q34466828

about

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Daratumumab: First Global Approval.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Novel Immunotherapies for Multiple Myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.An update on the role of daratumumab in the treatment of multiple myeloma.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.The safety of daratumumab for the treatment of multiple myeloma.Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.The Challenges of Daratumumab in Transfusion Medicine.Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody.Role of daratumumab in transfusion medicine: a must know entity.Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.How do I work up pretransfusion samples containing anti-CD38?An evaluation of storage time for dithiothreitol-treated reagent cells.Immunotherapy Strategies Against Multiple Myeloma.Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.Molecular immunohaematology round table discussions at the AABB Annual Meeting, Orlando 2016.Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?Transfusion management for patients taking an anti-CD38 monoclonal antibody.Daratumumab for the Treatment of Multiple Myeloma.Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.51. Jahrestagung der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI), Lübeck, 19.-21. September 2018, Abstracts

P2860

Q26745919-8592ABF7-AD32-4072-AD31-FFC47E2CCB53 Q26766718-09A9CFA9-314C-4665-AA2B-429E7693A15E Q33434683-2933915F-8E97-4ADC-BB51-67E52E0CAD42 Q33441476-A245229E-A5D6-4DA6-BE18-9EADA1CA321A Q34507354-D852A539-9987-4F37-885B-5B87C80F062C Q37076421-FEA6974D-95B4-4AF8-8B91-48A1F665E11E Q38640444-1B114EC7-180A-4B0B-A811-D64ED4423601 Q38742700-18B107E6-972A-47B1-BE37-0F042C666FDA Q38775700-D71068DC-5565-4C51-87E2-21DF02D30185 Q38792725-979DA3FC-CC66-4CEA-9844-5BBD1C9D4E17 Q38793959-9C8DEAEF-CE2D-4B08-B66F-E35FDF0FF35C Q38809499-FCDE760E-3095-485F-BA2A-89AC8E0FB77A Q38817467-33260C30-4BCE-4A5A-98BD-132F597DED7A Q38820002-CD62712D-7759-4C23-8C13-2687D444FC04 Q38824538-5DB938E4-6B44-4003-B132-F57E44B86AA6 Q38985014-B400F125-978F-4317-8C2A-D2A9B7EF08C1 Q38994343-97FC2753-1078-41A0-AB90-19398B94A045 Q38996881-7D6921D0-3C14-457D-834F-70FBE476FFDF Q39100317-52F077CD-74E3-4DE7-B56A-2BF9D00CFBB1 Q39169309-FA9771E5-C161-4A25-B78F-061B89CFCF29 Q39177792-F3C756D7-DEE9-4E72-BB18-2ABA7BC64F58 Q39417506-C0973179-6F31-4AE9-8F42-7A7F49FBE45B Q42003178-D8663957-2398-43D3-AEBA-F8F6DEAF1DBD Q45719678-52660027-1FAC-4958-9184-0187A07AC4A4 Q46173025-F6C32C2A-8757-494F-9B5F-FE5FDC62BE1F Q47614728-C7B80516-E121-4149-B84B-940448AA9BEF Q48187335-BE368915-6E43-481B-AB5C-B5CD1C796E54 Q49860157-06E5E3B9-3383-40F2-9295-99447D53DF19 Q49995864-4E5154B3-1862-498A-AE46-5BAA2C02F808 Q50211747-D03CB8ED-C25A-4893-ACF3-2BDA26A8F7D9 Q51412052-086028D0-724E-40E8-B52B-9B5095B9ED17 Q55021985-0230A99D-1646-46EA-8F17-B0DB189315DC Q55261498-0EF4CD2F-D441-40EA-AB7E-D97E02509864 Q55337411-FA2DD2B5-990A-4F1C-8565-64A075D53E73 Q55392778-508125CC-64EB-4863-9B12-1FE5129C657C Q58721513-ADE9FB14-F673-4716-BB7A-9112803E7FDF

P2860

Resolving the daratumumab interference with blood compatibility testing.

http://www.wikidata.org/entity/Q34466828

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Resolving the daratumumab interference with blood compatibility testing.

@ast

Resolving the daratumumab interference with blood compatibility testing.

@en

Resolving the daratumumab interference with blood compatibility testing.

@nl

type

label

Resolving the daratumumab interference with blood compatibility testing.

@ast

Resolving the daratumumab interference with blood compatibility testing.

@en

Resolving the daratumumab interference with blood compatibility testing.

@nl

prefLabel

Resolving the daratumumab interference with blood compatibility testing.

@ast

Resolving the daratumumab interference with blood compatibility testing.

@en

Resolving the daratumumab interference with blood compatibility testing.

@nl

P1433

Q34466828-6A9B576F-5A8E-4662-BE7E-28FC609F6600

P1476

Q34466828-73BD081E-EC5B-4783-BA86-147C0ECBF163

P2093

Q34466828-0004E134-74C9-4607-AD0A-3ACC4EEE2AC9

Q34466828-09AF2D9A-19D8-4B92-8029-374B1D87E764

Q34466828-1C688BCD-05FE-44A5-A31D-175183D6B48D

Q34466828-5AB506BF-634E-4164-A31C-4B601B7BE4B2

Q34466828-61527F06-C12C-49FF-9F6E-22DC86D4B2BE

Q34466828-6C7B116B-361B-4F79-AA19-B2708688CC95

Q34466828-9984E14E-F176-476A-8CA4-093545AB5351

Q34466828-9D0E46CE-7D18-41DF-B01F-0E6A23E12A6B

P2860

Q34466828-8FDBEEB2-1F92-46A6-9B76-F0DF03C319BE

Q34466828-C01CF2F2-9DF9-44A5-B1CA-2F621D99D503

Q34466828-CE3ED20C-CE93-42F3-B966-4EA37927367F

P304

Q34466828-C4353C50-7004-4E78-AD96-54A740F1AE27

P31

Q34466828-8535F996-4FE0-4FF3-B727-55108BBEABEA

P356

Q34466828-55A2A786-7C9B-4AF2-8F1D-C128D195EEF2

P433

Q34466828-6F7915CE-592C-4023-9CCD-1F54B688D8F3

P478

Q34466828-73A0196D-D316-4EBA-B27A-8B4210340FA8

P577

Q34466828-FD5D92AE-76BC-4DEB-A174-5ACD1AF795DE

P5875

Q34466828-4FC22CAE-401B-4535-8B6F-DF7663907425

P698

Q34466828-D8DDC316-4974-4B2B-96E9-B269DD3E46B1

P356

P1433

P1476

Resolving the daratumumab interference with blood compatibility testing.

@en

P2093

Bjoern Chapuy

http://www.w3.org/2001/XMLSchema#string

Claudia I Chapuy

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Maria D Aguad

http://www.w3.org/2001/XMLSchema#string

Parul Doshi

http://www.w3.org/2001/XMLSchema#string

Paul G Richardson

http://www.w3.org/2001/XMLSchema#string

Rachel T Nicholson

http://www.w3.org/2001/XMLSchema#string

Richard M Kaufman

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

The membrane-bound enzyme CD38 exists in two opposing orientations.

P304

1545-1554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/TRF.13069

http://www.w3.org/2001/XMLSchema#string

P433

6 Pt 2

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273466223

http://www.w3.org/2001/XMLSchema#string

P698

25764134

http://www.w3.org/2001/XMLSchema#string